You are here

Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco

YARDLEY, Pa., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will present clinical and health economic outcomes data at the 2019 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Francisco, California, February 22 - 25, 2019. Abstracts are available on the AAAAI Annual Meeting website located at annualmeeting.aaaai.org. XHANCE® (fluticasone propionate) nasal spray, 93 mcg, is approved by the U.S. Food and Drug Administration for the treatment of nasal polyps in patients 18 years of age or older.
Friday, February 15, 2019 - 07:00